These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8794167)

  • 21. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
    Boado RJ
    Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
    Huang C
    Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V).
    Qian N; Gao L; Dong L; Liu H; Fu J; Meng D; Gao X; Zhang J; Gao Y; Song H
    Protein Expr Purif; 2015 May; 109():1-6. PubMed ID: 25616235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of Fc-mediated effector functions of monoclonal antibodies.
    Strohl WR
    Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A thermostable enzyme as an experimental platform to study properties of less stable homologues.
    Lill H; Hisabori T; Groth G; Bald D
    Protein Eng Des Sel; 2004 Jul; 17(7):553-5. PubMed ID: 15333775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
    Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-LinK: A method for generating multicomponent cytochrome P450 fusions with variable linker length.
    Belsare KD; Ruff AJ; Martinez R; Shivange AV; Mundhada H; Holtmann D; Schrader J; Schwaneberg U
    Biotechniques; 2014 Jul; 57(1):13-20. PubMed ID: 25005689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An intermediate in the assembly of a pore-forming protein trapped with a genetically-engineered switch.
    Walker B; Braha O; Cheley S; Bayley H
    Chem Biol; 1995 Feb; 2(2):99-105. PubMed ID: 9383410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Your personalized protein structure: Andrei N. Lupas fused to GCN4 adaptors.
    Deiss S; Hernandez Alvarez B; Bär K; Ewers CP; Coles M; Albrecht R; Hartmann MD
    J Struct Biol; 2014 Jun; 186(3):380-5. PubMed ID: 24486584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fc fusion as a platform technology: potential for modulating immunogenicity.
    Levin D; Golding B; Strome SE; Sauna ZE
    Trends Biotechnol; 2015 Jan; 33(1):27-34. PubMed ID: 25488117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria.
    Qiu XQ; Wang H; Lu XF; Zhang J; Li SF; Cheng G; Wan L; Yang L; Zuo JY; Zhou YQ; Wang HY; Cheng X; Zhang SH; Ou ZR; Zhong ZC; Cheng JQ; Li YP; Wu GY
    Nat Biotechnol; 2003 Dec; 21(12):1480-5. PubMed ID: 14625561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
    Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
    Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid clearance of bacteria and their toxins: development of therapeutic proteins.
    Kunkel M; Vuyisich M; Gnanakaran G; Bruening GE; Dandekar AM; Civerolo E; Marchalonis JJ; Gupta G
    Crit Rev Immunol; 2007; 27(3):233-45. PubMed ID: 18197819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.
    Lu JX; Peng Y; Meng ZF; Jin LQ; Lu YS; Guan MX
    Biochem Biophys Res Commun; 2005 Aug; 334(1):157-61. PubMed ID: 15993840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.
    Sacco E; Metalli D; Spinelli M; Manzoni R; Samalikova M; Grandori R; Morrione A; Traversa S; Alberghina L; Vanoni M
    Biotechnol Adv; 2012; 30(1):233-43. PubMed ID: 21620943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.
    Morris NP; Peters C; Montler R; Hu HM; Curti BD; Urba WJ; Weinberg AD
    Mol Immunol; 2007 May; 44(12):3112-21. PubMed ID: 17374396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.
    Bitonti AJ; Dumont JA
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1106-18. PubMed ID: 16997417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer.
    Huang YS; Wen XF; Wu YL; Wang YF; Fan M; Yang ZY; Liu W; Zhou LF
    Eur J Pharm Biopharm; 2010 Mar; 74(3):435-41. PubMed ID: 19995603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
    Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.